Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracerebroventricular 131I-omburtamab for neuroblastoma CNS/leptomeningeal metastases
2017-001828-22Phase 2Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Jan 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, single-arm trial of 131I-omburtamab in neuroblastoma and central nervous system neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Overall survival at 3 years. Started Jan 2018; status: terminated.
02
Drugs
131I-omburtamab
03
Conditions
neuroblastomacentral nervous system neuroblastoma
Beyond the preview
Go deeper on 2017-001828-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001828-22.